- Home
- KPRX vs IMRN Comparison
KPRX vs IMRN Comparison
Compare KPRX & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- IMRN
- Stock Information
- Founded
- KPRX 1998
- IMRN 1994
- Country
- KPRX United States
- IMRN Australia
- Employees
- KPRX N/A
- IMRN N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- KPRX Health Care
- IMRN Health Care
- Exchange
- KPRX Nasdaq
- IMRN Nasdaq
- Market Cap
- KPRX 9.1M
- IMRN 9.2M
- IPO Year
- KPRX N/A
- IMRN N/A
- Fundamental
- Price
- KPRX $2.90
- IMRN $1.88
- Analyst Decision
- KPRX Strong Buy
- IMRN Strong Buy
- Analyst Count
- KPRX 1
- IMRN 1
- Target Price
- KPRX $10.00
- IMRN $5.00
- AVG Volume (30 Days)
- KPRX 1.3M
- IMRN 25.2K
- Earning Date
- KPRX 08-08-2025
- IMRN 07-07-2025
- Dividend Yield
- KPRX N/A
- IMRN N/A
- EPS Growth
- KPRX N/A
- IMRN N/A
- EPS
- KPRX N/A
- IMRN N/A
- Revenue
- KPRX $20,000.00
- IMRN $4,048,286.00
- Revenue This Year
- KPRX N/A
- IMRN N/A
- Revenue Next Year
- KPRX N/A
- IMRN N/A
- P/E Ratio
- KPRX N/A
- IMRN N/A
- Revenue Growth
- KPRX N/A
- IMRN 82.90
- 52 Week Low
- KPRX $2.51
- IMRN $1.50
- 52 Week High
- KPRX $4.86
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- KPRX 43.33
- IMRN 58.70
- Support Level
- KPRX $2.87
- IMRN $1.68
- Resistance Level
- KPRX $3.22
- IMRN $1.94
- Average True Range (ATR)
- KPRX 0.18
- IMRN 0.09
- MACD
- KPRX -0.02
- IMRN 0.02
- Stochastic Oscillator
- KPRX 5.77
- IMRN 76.92
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.